ARCHIVES

Interim Funding: Noncompeting Renewals Reduced By 4 Percent, Competing Current Plus 7 Percent

This article is from The Cancer Letter archive.

Vol. 08 No. 02 | January 8, 1982

Download PDF Visit The Full Archive

Related Articles

ODAC Recommends Approval of Evista for Breast Cancer Risk Reduction.

July 27, 2007

CMS To Recognize NCCN’s Drug Compendium.

June 6, 2008

Clinical Trials Approved In August 2002 By NCI

September 27, 2002

ASCO, AACR Hold Last Joint annual Meeting, Vow to Encourage Basic-Clinical Interaction

May 28, 1993

NCAB Subcommittee Suggests Comp Centers Must Have Core Grants

September 22, 1978

Bill Pressures HCFA To Launch Project On Reimbursement for Cancer Trials

July 26, 1996